secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2026-05-22T20:05:17+00:00
Accession:  0001104659-26-065696
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec announces new PEDMARK data at ASCO showing hearing loss reduction in pediatric/AYA patients
--------------------------------------------------------------------------------

- Phase 2/3 STS-J01 study met primary endpoint: hearing loss 16-24% vs 56-63% historical control.
- Randomized Phase 1 trial of cisplatin +/- PEDMARK for metastatic germ cell tumor opened at City of Hope.
- Retrospective case series (9 AYA patients) shows PEDMARK feasible and does not compromise cisplatin antitumor activity.
- Real-world data in 15 head & neck cancer adults: PEDMARK safe ≥6h after cisplatin, hearing preserved.
- Company expands evidence base for PEDMARK in broader populations beyond current pediatric approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926065696/0001104659-26-065696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926065696/fencf-20260521x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-065696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer